"Horizon 2020"
European Community
THE PRODUCT
 |  |  |
|---|---|---|
 |  |  |
 |
THE MARKET
Western Europe and USA
• Lung, colon, ovary cancers new cases/ year: 700.000
• Tumors expressing Trop-2: 500.000
• Health services reimbursements: 30.000 €/ patient
• Target total sales: 15 billion €/ year
Example: Herceptin 7 billion € / year
-
Arius Biotech has been bought by Roche. Oncoxx antibodies shown superior to Arius antibodies in preclinical models. Roche has dropped efficacy tests on Arius antibodies because of inadequate performance
-
Livtech: later filing date (priority date 17may2010; european patent filed on the 17th may 2011; Oncoxx Biotech PCT filed on the 5th feb. 2009). No anti-cancer antibody synergy
-
Immunomedics - hRS7: no activity if not bound to toxins
-
Rinat-Pfizer Patent WO 2013/068946: later filing date versus Oncoxx (priority data 30apr2012; PCT filed on the 7th nov. 2012). No anti-cancer antibody synergy
-
Unsuitable antibodies (mixed light chains):
-
T16 public; hT16 Patent WO 98/12227
-
RS7 Patents WO03/074566, US2004/001825, US2007/212350 e US2008/131363
-
162-46.2 Public
-
COMPETITORS
THE COMPANY
-
Leadership in the field of Trop-2 research
-
Unique know-how on the molecule
-
Proprietary anti-Trop-2 antibodies
-
Major collaborators network
-
Two strategic US-approved PCT (WO 2010/035304; WO 2010/089782); two pending PCT
-
Efficacy in preclinical models
-
Advanced stage of research
-
Regulatory activity planning